Khalifa E, Mohammad H, Abdullah A, et al. - Researchers conducted a randomized controlled trial with the aim to determine the role of Dienogest pretreatment vs Gonadotropin-releasing hormone agonist (GnRHa) for endometriosis suppression in patients pursuing IVF treatment. They performed random allocation of 134 women with endometriosis-related infertility either to receive monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol), or to receive daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF. Although the groups showed no statistically significant difference with respect to ovarian stimulation, response parameters, and pregnancy outcomes, the Dienogest group had a lower cost of treatment, lower side effects, higher FertiQoL treatment scores and higher tolerability scores. Overall these findings suggest Dienogest to be a suitable and safe alternative for GnRHa pretreatment in endometriosis patients.